US Pharma MarketingAllen Institute launches $200M effort to turn brain atlas lessons into medicines
The Allen Institute is launching a $200 million initiative to explore specific neurodegenerative diseases and even develop drugs for those conditions. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
A Seattle-based nonprofit known for basic brain research is launching a $200 million initiative to translate its knowledge into drug development for neurodegenerative diseases, including Alzheimer's.
It's a major new direction for the Allen Institute ...
Source: Endpoints News